Reactivity: Forms active intermediate with carboxyl groups at pH 4.7–6.0 (optimum), then intermediate reacts with primary aminesġ-Ethyl-3-carbodiimide hydrochloride (EDC or EDAC) is a zero-length crosslinking agent used to couple carboxyl groups to primary amines.High-purity, crystalline reagent-use to create high-quality, activated derivatives.Soluble reaction byproducts-easily removed by washing with water or dilute acid.Water-soluble reagent-add directly to reactions in aqueous, physiological buffers.Neutral linkage-forms neutral amide bonds between carboxyls and amines.Several conjugation strategies-react EDC alone with target groups or include NHS or Sulfo-NHS to increase reaction efficiency or to stabilize active intermediate for later reaction to amines.Reaction target: activates carboxyl groups to conjugate to amino groups (primary amines).The format enables use of a fresh vial of reagent each time, eliminating the hassle of weighing small amounts of reagents and reducing concerns over reagent stability. ![]() The pre-weighed packaging prevents the loss of reagent reactivity and contamination over time by eliminating the repetitive opening and closing of the vial. Thermo Scientific No-Weigh products are specialty reagents provided in a pre-aliquoted format. A side reaction is the formation of an N-acylurea, which is usually restricted to carboxyls located in hydrophobic regions of proteins. Failure to react with an amine will result in hydrolysis of the intermediate, regeneration of the carboxyl, and release of an N-substituted urea. The intermediate is unstable in aqueous solutions and so two-step conjugation procedures rely on N-hydroxysuccinimide (NHS) for stabilization. EDC reacts with a carboxyl group first and forms an amine-reactive O-acylisourea intermediate that quickly reacts with an amino group to form an amide bond with release of an isourea by-product. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.Thermo Scientific Pierce EDC is a carboxyl- and amine-reactive zero-length crosslinker. The company assumes no duty to update the information to reflect subsequent developments. ![]() The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended Decemand the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update ![]() The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |